Valneva confirms clinical trial and regulatory submission timelines for its inactivated covid-19 vaccine candidate vla2001

Saint herblain (france), january 6 , 2022 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today confirms the previously communicated timelines of its clinical trials and regulatory submissions for its inactivated, adjuvanted covid-19 vaccine candidate, vla2001.
VALN Ratings Summary
VALN Quant Ranking